Drug intelligence / Profile preview

doxorubicin + nivolumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Doxorubicin + nivolumab is a combination therapy that pairs a cytotoxic anthracycline (doxorubicin) with an immune checkpoint inhibitor (nivolumab). Doxorubicin is capable of inducing immunogenic cell death (ICD), a specific type of tumor cell death that can trigger an adaptive immune response. Nivolumab is a PD-1 inhibitor that blocks the interaction between PD-1 and its ligands, enhancing T-cell function. The combination is hypothesized to create synergy in the ICD circuit, with doxorubicin's cytotoxic effects potentially enhancing the efficacy of nivolumab's immunotherapeutic action.

Targets

TOP2A (DNA topoisomerase II)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on doxorubicin + nivolumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + nivolumab.

Explore the full profile